However, the clinical efficacy of anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) in advanced EGFR mutant NSCLC or combination therapy of EGFR-TKIs and anti-PD-1/PD-L1 ICIs is still not clear yet63. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.